000170273 001__ 170273
000170273 005__ 20260410165451.0
000170273 0247_ $$2doi$$a10.1111/head.70086
000170273 0248_ $$2sideral$$a148819
000170273 037__ $$aART-2026-148819
000170273 041__ $$aeng
000170273 100__ $$aGarcía-Castillo, María Clara
000170273 245__ $$aEvaluation of the effectiveness and safety of anti-CGRPmonoclonal antibodies in patients with migraine andautoimmune diseases: IMMUNO-CGRP study
000170273 260__ $$c2026
000170273 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170273 5203_ $$aObjective: This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background: CGRP has an important role in migraine pathophysiology through neuronal modulation in the trigeminovascular nociceptive system and activation of neuro‐inflammatory cascades. We hypothesized that autoimmune diseases may influence treatment response and safety profiles in patients with migraine treated with anti‐CGRP treatments. Methods: This was a retrospective multicenter, age‐ and sex‐matched cohort study in headache units/headache clinics in Spain and United Kingdom between May 2024 and May 2025 including patients treated with CGRP monoclonal antibodies from prospectively collected cohorts. Patients were assessed for demographics, migraine‐related characteristics, treatment effectiveness (monthly migraine days [MMD] and/or monthly headache days [MHD]), and safety outcomes. The main outcome was the effectiveness measured by ≥50% response rate in MMD between the two groups. Secondary outcomes included other effectiveness measurements regarding the number of MMD and MHD and treatment emerging adverse events. Results: A total of 388 patients with migraine under anti‐CGRP treatments (194 with autoimmune diseases and 194 age‐ and sex‐matched controls without autoimmune diseases) were included. The proportion of patients achieving a ≥50% response rate in MMD was higher in patients without autoimmune diseases at 6 (69% vs. 53%; p = 0.006) and 9 months (74% vs. 52%; p = 0.006). Treatment emerging adverse events were comparable between the two groups (35% vs. 38%; p = 0.575). Patients with autoimmune disease had a significantly lower likelihood of achieving a ≥50% response in MMD compared with those without autoimmune disease (adjusted odds ratio, 0.61; 95% confidence interval, 0.44–0.85; p = 0.006), independent of comorbid depression and medication overuse. Conclusions: Our study shows that anti‐CGRP treatments are effective and safe for patients with migraine regardless the presence of autoimmune diseases, although an increased treatment response in patient without autoimmune disorders compared to patients with autoimmune disorders was observed. These findings highlight the need for early intervention, tailored strategies, and vigilant monitoring in patients with migraine and autoimmune disorders. Further research should explore immunomodulatory approaches to enhance outcomes.
000170273 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/CM21-00178$$9info:eu-repo/grantAgreement/ES/ISCIII/PI24-01085
000170273 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000170273 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170273 700__ $$aSierra-Mencía, Álvaro
000170273 700__ $$aCaronna, Edoardo
000170273 700__ $$aToledo-Alfocea, Daniel
000170273 700__ $$aJaimes, Alex
000170273 700__ $$aUrtiaga, Sarai
000170273 700__ $$aCasas-Limón, Javier
000170273 700__ $$aMuñoz-Vendrell, Albert
000170273 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa, Sonia$$uUniversidad de Zaragoza
000170273 700__ $$aGarcía Martín, Valvanuz
000170273 700__ $$aMartín Ávila, Guillermo
000170273 700__ $$aPolanco, Marcos
000170273 700__ $$aVillar-Martínez, Maria Dolores
000170273 700__ $$aTrevino-Peinado, Cristina
000170273 700__ $$aRubio-Flores, Laura
000170273 700__ $$aSánchez-Soblechero, Antonio
000170273 700__ $$aPortocarrero Sánchez, Leonardo
000170273 700__ $$aLuque-Buzo, Elisa
000170273 700__ $$aLozano-Ros, Alberto
000170273 700__ $$aGago-Veiga, Ana Beatriz
000170273 700__ $$aDíaz-De-Terán, Javier
000170273 700__ $$aRecio García, Andrea
000170273 700__ $$aCanales Rodríguez, Javiera
000170273 700__ $$aGómez García, Andrea
000170273 700__ $$aGonzález Salaices, Marta
000170273 700__ $$aCampoy, Sergio
000170273 700__ $$aMínguez-Olaondo, Ane
000170273 700__ $$aManiataki, Stefania
000170273 700__ $$aGonzález-Quintanilla, Vicente
000170273 700__ $$aPorta-Etessam, Jesús
000170273 700__ $$aCuadrado, María-Luz
000170273 700__ $$aGuerrero Peral, Ángel Luis
000170273 700__ $$aPozo-Rosich, Patricia
000170273 700__ $$aRodríguez-Vico, Jaime
000170273 700__ $$aHuerta-Villanueva, Mariano
000170273 700__ $$aPascual, Julio
000170273 700__ $$aGoadsby, Peter J.
000170273 700__ $$aGonzalez-Martinez, Alicia
000170273 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000170273 773__ $$g(2026), [12 pp.]$$pHeadache$$tHeadache$$x0017-8748
000170273 8564_ $$s770768$$uhttps://zaguan.unizar.es/record/170273/files/texto_completo.pdf$$yVersión publicada
000170273 8564_ $$s2237865$$uhttps://zaguan.unizar.es/record/170273/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170273 909CO $$ooai:zaguan.unizar.es:170273$$particulos$$pdriver
000170273 951__ $$a2026-04-10-13:45:38
000170273 980__ $$aARTICLE